Financial Gravity Asset Management, Inc. Tg Therapeutics, Inc. Transaction History

Financial Gravity Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jun 26, 2024	BUY	$13.02 - $21.3 $26 - $42	2 Added 66.67%	5 $80,000
Q1 2024 May 13, 2024	BUY	$13.02 - $21.3 $156 - $255	12 Added 400.0%	15 $232,000
Q4 2023 Jun 26, 2024	SELL	$6.68 - $18.81 $80 - $225	-12 Reduced 80.0%	3 $58,000
Q3 2023 Nov 15, 2023	SELL	$8.36 - $26.5 $183 - $583	-22 Reduced 88.0%	3 $0
Q2 2023 Aug 08, 2023	BUY	$15.48 - $35.0 $387 - $875	25 New	25 $152,000
Q4 2022 Feb 15, 2023	BUY	$5.01 - $11.83 $60 - $141	12 New	12 $10,000
Q2 2021 Aug 11, 2021	SELL	$32.5 - $48.96 $32 - $48	-1 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$41.61 - $54.3 $41 - $54	1 New	1 $29,000
Q2 2020 Aug 13, 2020	SELL	$8.9 - $21.84 $364 - $895	-41 Closed	0 $0
Q3 2018 Oct 31, 2018	BUY	$5.15 - $14.0 $211 - $574	41 New	41 $0

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.